Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

• Main Authors: Thomas Mehrling, Daniel Soltis
• Format: Article
• Language: English
• Published: MDPI AG 2018-02-01
• Series: Antibodies
• Subjects: antibody-drug conjugate; smart chemotherapy; targeted treatment; solid tumours; haematological malignancies
• Online Access: http://www.mdpi.com/2073-4468/7/1/11

Although considerable progress has been made in the field of cancer chemotherapy, there remains a significant unmet medical need, with a requirement to move away from traditional cytotoxics and explore novel, smarter chemotherapeutic approaches. One such example of the smart chemotherapy approach is antibody-drug conjugates (ADCs), which consist of an antibody that binds selectively to a cancer antigen linked to a cytotoxic agent. When developing an ADC, it may be necessary to produce a variety of constructs to fully assess the optimal configuration for the molecule. By testing ADCs prepared using a range of cytotoxic agents, linkers, or different antibodies, it is possible to fully assess the optimal approach for this treatment modality before advancing to the clinic. Since the development and approval of first-generation ADCs, significant improvements in development technology have occurred. Here, we consider the advances made within the field of ADCs, focusing on the development of EDO-B278 and EDO-B776, both of which have demonstrated efficacy in preclinical testing. Although some limitations remain in this field of development, the potential reduction in toxicity offered by ADCs justifies the investment in research to find workable solutions that could ultimately provide patients with superior outcomes.